Approvals

New EU Approvals

 

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include Hympavzi, Pfizer's treatment for adults and adolescents with severe hemophilia A or B without inhibitors.

Why The EMA Said No To Kizfizo And Cinainu

 

The European Medicines Agency has recommended against EU marketing approval for two drugs targeting children.

Gohibic For SARS-CoV-2-Induced ARDS Among Eight New Drugs To Win EMA Nod

Patients in the ICU continue to die from SARS-CoV-2-induced acute respiratory distress syndrome, says InflaRx, which is one of companies whose product the European Medicines Agency today announced should be approved for marketing in the EU.

Leqembi Secures EMA Thumbs Up For Narrower Indication

 

After an initial rejection, the European Medicines Agency now says that Eisai/Biogen’s Alzheimer’s disease drug should be approved, albeit with a recommendation for initial generic screening and ongoing safety scans.


Japan Recommends Approval Of Brukinza, Balversa

 
• By 

Along with several new positive approval recommendations, Japan's proceeding to grant Sakigake designation to two drugs including a DMD gene therapy discovered through public collaboration. Meanwhile, the PMDA has opened a new full-time office in the US.

Déjà Vu In England: Lilly’s Alzheimer’s Drug Kisunla Gets MHRA Yes, But NICE Says No

 

The UK’s drug regulator has approved Eli Lilly’s early Alzheimer’s drug Kisunla, but England’s health technology assessment agency NICE said that the product “does not currently demonstrate value” for the National Health Service.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Eisai Fights Back After Australia Rejects Alzheimer's Drug Leqembi

 

The Therapeutic Goods Administration appears to share similar safety concerns regarding Leqembi as those expressed by the European Medicines Agency when it rejected the drug in July.


EMA Schedules High-Stakes Meetings With Drug Makers

 

The sponsors of medicines that are nearing the end of the regulatory review cycle in the EU could this week be asked to explain why the European Medicines Agency should recommend approving their products.

Janssen’s Nipocalimab Among Six New EU Filings

 

Nipocalimab is an investigational FcRn blocker for treating generalized myasthenia gravis that was also recently filed for regulatory review in the US.

Singapore Releases eCTD Specification Package As Companies Prepare For Portal Launch

 

Companies will initially be able to submit their dossiers to the Health Sciences Authority via the eCTD portal on a voluntary basis.

EMA Clarifies Quality And Equivalence Testing Expectations For Cutaneous Products

 

New guidance from the European Medicines Agency explains how in vitro and in vivo models may be used instead of clinical data for the purpose of establishing therapeutic equivalence in a stepwise approach.


UK MHRA First-Half New Drug Approvals Show Overwhelming Use Of EU Reliance Procedures

 
• By 

The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.

Flu Vaccine Nasal Spray Is Latest Prescription Drug Available Direct To US Consumers

 

The FDA approved MedImmune’s FluMist for home use to prevent flu caused by virus subtypes A and B in individuals age 2 through 49 years old.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

US FDA Closes Out Problem Applications One Federal Register Notice At A Time

 
• By 

The refuse-to-approve decision for i02/Intarcia’s Type 2 diabetes combination product is the latest example of the FDA reaching final negative decisions on challenging regulatory cases.


EU OKs Imvanex Vaccine In Younger People To Help Tackle Mpox Spread In Africa

 
• By 

The World Health Organization has also prequalified the Bavarian Nordic vaccine to enable broader and timely access.

Orphans Elahere, Hetronifly & Hympavzi Among Eight New Products Set For EU Approval

 

The European Medicines Agency has recommended the pan-EU approval of three rare disease drugs: Pfizer’s Hympavzi, Henlius Biotech’s Hetronify and ImmunoGen’s Elahere in addition to five other new medicines.

EMA Tackles Hurdles To Using Single-Arm Trial Data For Pivotal Evidence In Filings

 

The European Medicines Agency has highlighted issues for drug developers to consider when seeking to submit clinical data from SATs as the pivotal evidence in their marketing authorization applications instead of randomized controlled trial data.

Evergreen With Envy: Halozyme’s Subcutaneous Conversions Grow As Rivals Hope To Break In

 

Halozyme’s Enhanze technology has now brought seven monoclonal antibodies, including Ocrevus and Tecentriq, from IV to subcutaneous delivery, but Alteogen and other high-concentration formulation players hope to join the party as Medicare pricing issues help drive interest.